All In Biotech

Drug Trial Radar · NCT03363373

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

122

Planned (sponsor's estimate)

Start

Apr 3, 2018

Primary completion

Jun 30, 2026

Study completion Apr 2028

Sponsor

Lead sponsor
Y-mAbs TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2

Conditions

  • Neuroblastoma

Interventions

  • GM-CSF + NaxitamabBiological

    Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response rate during Naxitamab treatmentTime frame: 101 weeks

Locations

20 sites in 9 countries. Site status is shown where the registry gives one.

  • Riley Hospital for Children

    Indianapolis, Indiana

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • The Hospital for Sick Children

    Toronto, Canada

  • Rigshospitalet

    Copenhagen, Denmark

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Germany

  • Johannes Gutenberg-Universität

    Mainz, Germany

  • University Hospital Regensburg

    Regensburg, Germany

  • Hong Kong Children's Hospital

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Tata Memorial Centre

    Mumbai, India

  • Ospedale Pediatrico Bambino Gesù

    Rome, Italy

  • Giannina Gaslini Hospital

    Genoa, Genoa, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Milan, Italy

  • Hospital Sant Joan de Déu

    Barcelona, Spain

  • Hospital Infantil Universitario Niño Jesús

    Madrid, Spain

  • Hospital Universitario Virgen Del Rocío

    Seville, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

  • The Royal Glasgow Children's Hospital

    Glasgow, United Kingdom

  • Leeds General Infirmary

    Leeds, United Kingdom

  • University Hospital Southampton

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.